Bulletin, Institute

CARB-X Updates

September 2017

Read the latest of CARB-X:

  • CARB-X publishes first annual report. Highlighting its pipeline of 18 promising research projects with 8 new classes of antibiotics to treat the most urgent drug-resistant gram-negative bacteria. Read More
  • CARB-XED, GARDP, ASM, and ESCMID hosted Antibiotic Bootcamps at ASM-ESCMID conference on antibiotic R&D Read More
  • CARB-X-funded Proteus IRC’s device can see through the human body Read more
  • Powered by CARB-X company Tetraphase Pharmaceuticals announces submission and validation of IV Eravacycline Marketing Authorization Application for the treatment of complicated intra-abdominal infection Read More
  • Powered by CARB-X company Forge Therapeutics and its strategic alliance partner Evotec present preclinical efficacy data on Forge’s LpxC antibiotic program at the 2017 ASM/ESCMID Conference Read More
  • Entasis announces $31.9 million extension of Series B financing to advance the company’s programs to treat multidrug-resistant gram-negative infections Read More
  • The Global Antibiotic Research and Development Partnership (GARDP), which just received €56.6M of funding from six EU countries, the Wellcome Trust and South Africa, are planning to collaborate with CARB-X to work on breaking antibiotic resistance Read More